Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine
Show others and affiliations
2018 (English)In: Current pharmaceutical design, Vol. 24, no 32, p. 3778-3790Article in journal (Refereed) Published
Abstract [en]

A complex framework of interacting partners including genetic, proteomic, and metabolic networks that cooperate to mediate specific functional phenotypes drives human biological processes. Recent technological and analytical advances in "omic" sciences allow the identification and elucidation of reprogramming biological functions in response to perturbations in cells and tissues. To understand such a complex system, biological networks are generated to reduce the complexity into relatively simple models, and the integration of these molecular networks from different perspectives is implemented for a holistic interpretation of the entire system. Ultimately, network-based methods will effectively facilitate the development and improvement of precision medicine by directing therapies based on the underlying biology of a given patient's disease. The goal of precision medicine is to identify novel therapeutic strategies that can be optimized for each disease type or each patient based on the underlying genetic, environmental, and lifestyle factors. Pharmaco-omics analyses based on an integration of pharmacology and various "omics" data types can be employed to develop effective treatment strategies using particular drugs and doses that are tailored to each individual. In the current review, we first present the core elements of network-based systems biology in the context of pharmaco-omics followed by integration of multi-omics data using various biological networks. Next, we provide an opening into precise medicine and drug targeting based on network approaches. Lastly, we review the current significant efforts as well as the accomplishments and limitations in precise drug targeting with the utility of network-based guided drug discovery methods for effective treatment of breast cancer. 

Place, publisher, year, edition, pages
NLM (Medline) , 2018. Vol. 24, no 32, p. 3778-3790
Keywords [en]
breast cancer, Drug discovery, drug repositioning, network-based, pharmaco-omics, precision medicine.
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:kth:diva-246556DOI: 10.2174/1381612824666181106095959ISI: 000455871200006Scopus ID: 2-s2.0-85060397141OAI: oai:DiVA.org:kth-246556DiVA, id: diva2:1304523
Note

QC 20190412

Available from: 2019-04-12 Created: 2019-04-12 Last updated: 2019-04-12Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 8 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf